- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02215174
Rosuvastatin Interethnic PK Study (RST)
Rosuvastatin Pharmacokinetic (PK) Study in Caucasian and Asian Morbid Obese Patients
Statins are the first-line and most commonly prescribed drugs for the prevention of cardiovascular diseases and stroke in the world. Our preliminary studies suggest that Caucasians might have a higher risk of developing potentially life-threatening drug-drug interactions than Asians when taking statins. Drug-drug interactions occur in the body when two or more drugs interact in a way that alters their effectiveness and/or toxicity. These interactions are becoming an increasingly severe problem with statin usage since patients at higher risk for cardiovascular diseases also take statins combined with many other drugs, such as antihypertensive and diabetic drugs. Our study is aimed at understanding the molecular factors and providing a sound basis for the interethnic dosage and response differences for statins.
Drug-transporting proteins in intestine and liver tissues are responsible for taking up statins into the blood. It is hypothesized that there are interethnic function differences of these proteins and that they account for differences in statin blood levels between Caucasians and Asians and the frequency and/or severity of their respective drug-drug interactions. A clinical study will be conducted with Caucasian and Asian subjects undergoing gastric bypass surgery so excess intestine and liver tissue can be acquired as part of the standard procedure. Protein levels will be quantified in the tissues and correlate them with different statin blood levels.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 82445
- E-Da Hospital
-
-
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects that are scheduled for bariatric surgery.
- Subjects that are able and willing to donate surplus intestinal tissue.
- Subjects with solute carrier organic anion transporter *1 (SLCO1B1) and breast cancer resistant protein (BCRP) 421CC genotypes.
- White/Caucasian/European and Asian/East Asian heritage individuals, male or female, 18 years of age or older.
- BMI between 30-55 kg/m2
- Be able to read, speak, and understand English(UCSF) and Chinese(Taiwan).
- Subjects capable of providing informed consent and completing the requirements of the study.
Exclusion Criteria:
- Subjects with active liver and kidney problems, severe cardiovascular diseases, type I diabetes, advanced pulmonary disease, and cancers.
- Subjects on chronic prescription or over the counter medication that have previously been reported to exhibit drug-drug interactions with rosuvastatin and cannot be stopped two weeks prior to and during the study, including gemfibrozil, cyclosporine, atazanavir, lopinavir and ritonavir.
- Subjects incapable of multiple blood draws (HCT < 30mg/dL).
- Subjects with a history of rhabdomyolysis.
- Subjects with a history of drug-related myalgias.
- Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias.
- Subjects with a history of GI bleed or peptic ulcer disease.
- Subjects with a recent history of trauma.
- Subjects who smoke tobacco or have ongoing alcohol or illegal drug use.
- Subjects who are pregnant, lactating, or trying to conceive during the study period.
- Subjects allergic to rosuvastatin or any known component of the medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Asians
Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
|
Rosuvastatin 20mg po x1
Other Names:
|
Experimental: Caucasians
Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
|
Rosuvastatin 20mg po x1
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area-under-the-concentration curve (AUC) of rosuvastatin
Time Frame: 0,1,2,3,4,5,6,8,12,24,36,48 hr post dosing
|
0,1,2,3,4,5,6,8,12,24,36,48 hr post dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in oral clearance of rosuvastatin
Time Frame: Pre-surgery period: 48 hr after dosing; post-surgery period: 48 hr after dosing. Two periods separated by at least two months.
|
Changes in oral clearance of rosuvastatin within gastric bypass surgery will be analyzed using the ratio of areas under the systemic concentration curves (AUCs) from before to after surgery using the bioequivalence criteria of 80-125%.
The oral clearance will be calculated based on the plasma data from each of the blood draws after the dosing period is completed (48hr).
The pre and post surgery period are separated by at least a 8-week recovery period.
|
Pre-surgery period: 48 hr after dosing; post-surgery period: 48 hr after dosing. Two periods separated by at least two months.
|
Descriptive comparison of messenger ribonucleic acid (mRNA) and protein expression in the tissues
Time Frame: Day of the surgery
|
Tissue samples will be collected on the day of the surgery.
|
Day of the surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Leslie Benet, PhD, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-13695.
- 14-13695 (Other Identifier: University of California, San Francisco)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Statin Pharmacokinetics Pre and Post Gastric Bypass Surgery
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingGastric Bypass | Sleeve Gastrectomy | Post Bariatric Surgery | Hypoglycemia After Gastric BypassUnited States
-
Medical University of South CarolinaCompletedGastric Bypass Surgery Pain ManagementUnited States
-
Mayo ClinicCompletedKetamine | Laparoscopic Gastric Bypass SurgeryUnited States
-
National Nutrition and Food Technology InstituteUnknownGastric Bypass SurgeryIran, Islamic Republic of
-
Hvidovre University HospitalUnknownObesity | Bone Loss | Gastric Bypass SurgeryDenmark
-
University Health Network, TorontoCompletedObesity | Opioid Consumption | Gastric-bypass SurgeryCanada
-
Amirsalar SamkaniHvidovre University HospitalCompletedBariatric Surgery (Gastric Bypass)Denmark
-
Kirstine Nyvold Bojsen-MoellerUniversity of CopenhagenUnknownOverweight | Bariatric Surgery (Gastric Bypass)Denmark
-
Vanderbilt University Medical CenterTerminatedGlucose Intolerance | Gastric Bypass SurgeryUnited States
-
Hospices Civils de LyonRecruitingPost-operative Complications After Colorectal Surgery | Post-operative Complications After Gastric Surgery | Post-operative Complications After Bariatric SurgeryFrance
Clinical Trials on Rosuvastatin
-
AstraZenecaCompletedDyslipidemia | Kidney DiseaseUnited States, Puerto Rico
-
Kobe UniversityCompletedCoronary Artery Disease Progression
-
Yuhan CorporationCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Ottawa Hospital Research InstituteUnknownVenous ThromboembolismCanada, Norway
-
Gachon University Gil Medical CenterDaewoong Pharmaceutical Co. LTD.UnknownCoronary Artery DiseaseKorea, Republic of
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Alvogen KoreaCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedUnknownHealthyKorea, Republic of
-
Organon and CoCompleted